$PFNX News
Last published 4y ago
- 4y agoIBIOPFNXPipeline Therapeutics Appoints Eef Schimmelpennink to its Board of DirectorsBusiness WirePipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directo
- 5y agoARCTANABPFNXTransCode Therapeutics Announces Key AppointmentsBusiness WireBOSTON--(BUSINESS WIRE)--TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a new member to its Advisory Board.
- 5y agoPFNXPfenex Inc. vs GlaxoSmithKline Biologicals SA - AIA Trial, TerminationUS Patent Trial and Appeal Board
- 6y agoPFNXGlaxoSmithKline Biologicals SA vs Pfenex Inc. - AIA Trial, TerminationUS Patent Trial and Appeal Board
- 6y agoLGNDPFNXLigand Announces Expiration of Tender Offer for Shares of Pfenex Inc.Business WireSAN DIEGO, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent pay ...
- 6y agoVARPFNXSBPHPRNBMoore Kuehn Encourages SBPH, PFNX, VAR, and PRNB Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoLGNDPFNXLigand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value ri ...
- 6y agoPFNXPfenex, Inc vs GlaxoSmithKline Biologicals SA - AIA Trial, TerminationUS Patent Trial and Appeal Board
- 6y agoNTNPRNBMNTAPFNXMoore Kuehn Encourages NTN, PRNB, MNTA, and PFNX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoLGNDPFNXLigand to Acquire Pfenex Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Pfenex Inc. (NYSE American: PFNX) today announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis. In addition, Ligand will pay $2.00 per share or $78 million as a Contingent Value Right ...
- 6y agoPFNXPfenex Reports Second Quarter 2020 Results and Provides Business UpdateGlobeNewswireCommercialization and launch of first royalty bearing products position company for next phase of growthMultiple U.S. health plans add Teriparatide Injection to their formulary upon its June 2020...
- 6y agoPFNXPfenex to Announce Second Quarter Financial Results on August 6GlobeNewswireSAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market...
- 6y agoPFNXPfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business UpdateGlobeNewswirePositive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorizationPfenex’s commercial partner Adalvo entered into...
- 6y agoPFNXPfenex to Participate in the William Blair Growth Stock ConferenceGlobeNewswireSAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat...
- 6y agoPFNXPfenex Reports First Quarter 2020 Results and Provides Business UpdateGlobeNewswireSAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform,...
- 6y agoPFNXPfenex to Announce First Quarter 2020 Financial Results on May 7GlobeNewswireSAN DIEGO, April 24, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market...
- 6y agoPFNXPfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence DeterminationGlobeNewswireSAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the...
- 6y agoPFNXPfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11GlobeNewswireSAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019,...
- 6y agoPFNXPfenex to Present at the Piper Jaffray 31st Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
- 6y agoPFNXPfenex to Present at the Evercore ISI HealthCONx Conference 2019GlobeNewswireSAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
- 7y agoPFNXPfenex Announces Management ChangeGlobeNewswireSAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief...
- 7y agoPFNXPfenex to Present at the Jefferies 2019 London Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Jefferies...
- 7y agoPFNXPfenex Reports Positive Results for PF708 Comparative Use Human Factors StudyGlobeNewswireStudy results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks Pfenex believes the study...
- 7y agoPFNXPfenex Provides Update for PF708 Outside the United StatesGlobeNewswireNew Exclusive Commercialization Agreements in South Korea, Canada, and Israel Submission of Marketing Authorization Application for PF708 in Saudi Arabia Potential approval of PF708 in the EU as...
- 7y agoSOLYAKCALVGOPFNX+1Biotech Brief: U.S. Medical Technology Market Projected To Exceed $200 Billion By 2023PR NewswireMedical device manufacturing remains a strong market, driven by technological developments, an aging population, and increases in chronic and...
- 7y agoPFNXPfenex Receives U.S. FDA Approval for PF708 to Treat OsteoporosisGlobeNewswirePfenex earns a $2.5M milestone payment from Alvogen for U.S. approval Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019 SAN DIEGO,...
- 8y agoPFNXPfenex, Inc (PFNX) CEO Eef Schimmelpennink on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoPFNXPfenex's (PFNX) CEO Evert Schimmelpennink on Q4 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoPFNXPfenex's (PFNX) CEO Eef Schimmelpennink on Q2 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoPFNXPfenex's (PFNX) CEO Patrick Lucy on Q1 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoPFNXPfenex's (PFNX) CEO Bert Liang on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts